MRI-Guided radiation aims to safely boost liver tumor treatment
NCT ID NCT04020276
First seen Jan 10, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This early-phase trial is testing whether MRI-guided radiation therapy (SBRT) can be given at higher doses safely to people with cancer that has spread to the liver. Up to 32 participants will receive 5 radiation sessions over 1.5 to 2 weeks. The main goal is to find the highest dose that does not cause serious side effects within the first month.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic Body Radiation Therapy (SBRT) with real-time MRI guidance
What this could lead to
If successful, this could establish a safer, more effective radiation dose for treating liver metastases, potentially improving tumor control with fewer side effects.
What could go wrong
This is an early phase I trial with only 32 participants, focused on safety and dosing. It may not lead to better outcomes, and there is a risk of radiation-related toxicity.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.